We’re ScreenPoint Medical
Decision support that truly supports
We’re ScreenPoint Medical
We are bringing AI to the fight against breast cancer with leading clinical evidence and the latest deep learning technology.
Improve patient outcomes
Every day, we work with radiologists in clinical practice and research to continually improve the proven deep learning algorithms in Transpara®. Our goal? Give women and their providers confidence in screening mammography.
Deep learning from the start
Because not all AI is the same, our origins matter to your results. ScreenPoint Medical was founded in 2014 by Professor Nico Karssemeijer and Professor Sir Michael Brady, world leading experts in quantitative breast image analysis and computer aided detection.
See why users trust Transpara
We are now prospectively implementing Transpara in our screening program and we are very excited to see the results from our prospective trial. Even better, we have observed that the latest version of Transpara has significantly improved the detection performance of the system, and a higher sensitivity is achieved at high specificity.
Dr Alvarez Benito
Consultant Radiologist, Hospital Universitario Reina Sofia in Cordoba, Spain
We are at the forefront of one of the first prospective studies with Transpara. As we will implement Transpara in a real-life screening setting in Ostergotland County, we aim to improve the quality of the breast cancer screening program while at the same time safely reduce the workload of breast radiologists.
Håkan Gustafsson
Deputy Director CMIV, AI Coordinator at Region Östergötland
Transpara may allow discriminating studies, which require more attention and selection of those, which may be handled with single reading for example. It may thus contribute significantly to both risk adapted screening and optimum assignment of resources.
Professor Sylvia H Heywang-Köbrunner
Radiologist, Head of the Referenzzentrum Mammographie Munich, Germany
Transpara has the potential to detect specific cancers earlier. I can think of 1-2 recent cases with calcifications, where Transpara detected a cancer earlier that was not easily visible on a mammogram.
Dr. Brian Englander, MD
Robert E. Campbell Professor of Clinical Radiology, Perelman School of Medicine Chairman, Department of Radiology, Pennsylvania Hospital Penn Center for Global Health Scholar
I use Transpara all the time, and won’t read another 3D mammogram without it. The product fits seamlessly into our workflow, and we have found over time it has increased our mammography workflow. Thanks to the technology’s score card we are also able to focus on those high risk patients first, and get those patients the care they may need faster.
Dr. Daniel Gurrell, MD
Vice President and Associate Medical Director at University Diagnostic Medical Imaging P.C.USA
Transpara increases my confidence and efficiency going through a screening mammography session. I have more focus especially with the higher risk cases thanks to their Intuitive Triage software.
Dr. Roger Yang, MD, FACR
President, University Radiology Group
Improve patient outcomes
Our partners, your workflow
At ScreenPoint, we know that breast imaging – and particularly breast screening – cannot function without effective workflow. To support our customers, we have designed an offering that is flexible and environment agnostic. Transpara works on 2D and 3D acquisitions, and our detection algorithm works on gantries from every major manufacturer. Regardless of your workflow, we want to fit seamlessly into your toolkit, so we work hard to ensure a seamless integration regardless of acquisition and reading environments.
